{"id":36887,"date":"2026-04-01T10:47:00","date_gmt":"2026-04-01T14:47:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36887"},"modified":"2026-03-08T14:25:04","modified_gmt":"2026-03-08T18:25:04","slug":"patent-gaps-pay-the-regional-launch-windows-hidden-inside-abandoned-drug-patents","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/patent-gaps-pay-the-regional-launch-windows-hidden-inside-abandoned-drug-patents\/","title":{"rendered":"Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets they consider too small to bother with. They make strategic decisions to let protection lapse in countries where enforcement looks expensive and returns look thin. And every time they do, they hand a competitor a legal entry point.<\/p>\n\n\n\n

Patent abandonment arbitrage \u2014 the practice of identifying, mapping, and exploiting geographic gaps in drug patent protection \u2014 is one of the least-discussed, most-profitable strategies in pharmaceutical business development. It sits at the intersection of patent law, regulatory affairs, and competitive intelligence, and the companies that execute it well consistently beat rivals to market by two, three, or five years. In some cases, they enter markets where the originator assumed it had full protection for another decade.<\/p>\n\n\n\n

This article explains how it works. You will learn the mechanics of patent lapsing across major jurisdictions, the tools analysts use to find abandoned rights, the case studies that prove the strategy delivers returns, the legal traps that destroy companies that move carelessly, and the frameworks that sophisticated players use to turn patent gap analysis into a repeatable business development process.<\/p>\n\n\n\n

The professionals who read this \u2014 business development executives, IP counsel, generic manufacturers, biosimilar developers, and investment analysts covering the pharmaceutical sector \u2014 already know that generic entry timing is the single biggest determinant of revenue in this industry. What many do not know is how much of that timing advantage comes not from patent challenges or Paragraph IV litigation, but from patents that were simply never filed, never maintained, or never validated in the markets where opportunity lives.<\/p>\n\n\n\n

\n\n\n\n

The Anatomy of Patent Abandonment<\/strong><\/h2>\n\n\n\n

Before you can exploit a lapsed patent, you need to understand exactly how patents die. Patent death comes in four distinct forms, each with different implications for competitive strategy.<\/p>\n\n\n\n

Failure to Pay Maintenance Fees<\/strong><\/p>\n\n\n\n

In the United States, patents require maintenance fees at 3.5, 7.5, and 11.5 years from grant. Miss a payment, and the patent lapses. The USPTO provides a six-month grace period for late payment with a surety fee, but after that window closes, the patent enters what is legally termed “expired” status for failure to maintain. The U.S. Patent and Trademark Office records these lapses publicly, and they are searchable.<\/p>\n\n\n\n

Globally, maintenance fee structures vary considerably. The European Patent Office charges annual renewal fees that increase progressively from the third year onward, reaching several thousand euros annually for late-stage patents. National patent offices within Europe require separate national renewal fees after a European patent is granted and validated nationally. The United Kingdom Intellectual Property Office, the German Patent and Trade Mark Office, and the French National Institute of Industrial Property each have their own schedules. Miss a fee in Germany, and the patent lapses in Germany while remaining alive in France, Spain, and Italy.<\/p>\n\n\n\n

This fee-based system creates the most common form of abandonment, particularly in smaller markets. A U.S. pharmaceutical company holding a composition-of-matter patent on a cardiovascular molecule may choose to pay maintenance fees in the United States, the European Union’s five largest economies, Japan, and Canada \u2014 and decide that Brazil, Mexico, South Africa, and Turkey simply do not justify the cost. For that molecule, those four countries may be effectively open territory from day one of patent grant, even while the originator enjoys full protection in developed markets.<\/p>\n\n\n\n

Strategic Abandonment and Non-Validation<\/strong><\/p>\n\n\n\n

The European Patent Convention allows applicants to file a single patent application at the EPO and receive a granted European patent \u2014 but that grant is merely a bundle of rights that must be activated country by country through national validation. Each national validation requires a translation (in some countries), a national filing fee, and ongoing annual renewal fees. Spain requires a translation into Spanish. Italy has historically required an Italian translation. Poland requires Polish. These costs add up, and originator companies routinely decide to validate in only a subset of the 38 EPC member states.<\/p>\n\n\n\n

The practical consequence is predictable. A blockbuster drug patent validated in the United Kingdom, Germany, France, Italy, and Spain may have no legal protection whatsoever in Portugal, Romania, Bulgaria, Croatia, or Slovakia. A generic manufacturer targeting any of those non-validated markets can launch without any infringement risk related to that composition-of-matter patent, provided no national patent was filed directly through the national office either.<\/p>\n\n\n\n

Strategic abandonment also occurs for substantive reasons. Companies occasionally abandon patents they view as weak \u2014 applications where the prosecution history makes the claims look narrow, where prior art emerged after filing that undermines novelty, or where a formulation patent covers a product that has been superseded by a newer version. These abandoned applications are public record in most jurisdictions, and they create both geographic and temporal opportunities for competitors.<\/p>\n\n\n\n

Procedural Abandonment and Prosecution Failure<\/strong><\/p>\n\n\n\n

Patent prosecution is not a passive process. Applicants must respond to office actions from patent examiners within statutory deadlines, typically two or three months from the date of the office action, with extensions available for additional fees. Failure to respond within the extended period results in abandonment for failure to prosecute.<\/p>\n\n\n\n

In the United States, the USPTO’s Patent Center database records these abandonments alongside the full prosecution history, meaning competitors can see exactly what the examiner rejected and why, which is useful intelligence for assessing whether related patents in the same family might face similar vulnerabilities.<\/p>\n\n\n\n

International applications filed under the Patent Cooperation Treaty \u2014 the dominant mechanism for multinational patent filing in pharmaceuticals \u2014 must enter national phase within 30 or 31 months from the earliest priority date. Missing national phase entry deadlines in specific countries kills the application in those countries permanently, absent extraordinary circumstances. Companies that file PCT applications and then face resource constraints, change strategic direction, or simply fail to track deadlines adequately end up with national phase lapses that create precisely the geographic gaps that arbitrageurs exploit.<\/p>\n\n\n\n

Terminal Disclaimers and Double Patenting Surrenders<\/strong><\/p>\n\n\n\n

Less common but worth understanding: terminal disclaimers filed to overcome obviousness-type double patenting rejections in the United States effectively limit a later-expiring patent to the same expiration date as an earlier-related patent. When the earlier patent lapses, the terminally disclaimed patent lapses with it, even if it would otherwise remain enforceable. This has caught several pharmaceutical companies off guard when maintenance fees on the earlier patent were inadvertently missed.<\/p>\n\n\n\n

\n\n\n\n

The Geographic Landscape of Patent Gaps<\/strong><\/h2>\n\n\n\n

Not all markets offer equal opportunity. The arbitrage value of a lapsed or unvalidated patent depends on the size of the pharmaceutical market, the regulatory pathway available for generic or biosimilar entry, and the level of enforcement risk even after patent rights expire.<\/p>\n\n\n\n

Developed Markets: High Value, Lower Gap Frequency<\/strong><\/p>\n\n\n\n

In the United States, the European Union’s five major markets, Japan, Canada, and Australia, originator companies protect their investments aggressively. Patent coverage is dense \u2014 composition-of-matter patents, polymorph patents, formulation patents, method-of-use patents, and process patents often create overlapping protection that can extend effective exclusivity well beyond the expiration of any single patent. Maintenance fees are paid diligently. Validation in major markets is standard practice.<\/p>\n\n\n\n

That said, gaps exist even here. The intersection of regulatory exclusivity and patent protection in the United States creates situations where companies allow patents to lapse because they are relying on separate regulatory exclusivity periods \u2014 five years for new chemical entities, three years for new clinical investigations, seven years for orphan drugs \u2014 and decide that paying patent maintenance fees on a compound already protected by regulatory exclusivity is redundant expenditure. When regulatory exclusivity ends and the patent has lapsed, the compound can be challenged without any patent hurdle.<\/p>\n\n\n\n

In Europe, the Supplementary Protection Certificate system allows originator companies to extend patent protection for up to five years to compensate for time spent in regulatory review. But SPCs must be applied for specifically in each EU member state, and companies occasionally miss SPC application deadlines in smaller markets. A missed SPC in Austria or the Netherlands does not generate headlines, but for a drug with $50 million in annual sales in those countries, the missed SPC means earlier generic entry than the originator planned.<\/p>\n\n\n\n

Emerging Markets: The Primary Arbitrage Opportunity<\/strong><\/p>\n\n\n\n

Brazil, India, China, Mexico, Russia, South Africa, Turkey, Indonesia, and the countries of Southeast Asia collectively represent the largest geographic pool of patent gap opportunities. Here, the combination of limited originator patent filing, inconsistent maintenance, complex local patent rules, and growing pharmaceutical markets creates conditions that are close to ideal for systematic arbitrage.<\/p>\n\n\n\n

India presents a particularly rich environment. Under Section 3(d) of the Indian Patents Act, patent protection for new forms of known substances \u2014 including salts, polymorphs, and formulations \u2014 requires demonstration of enhanced therapeutic efficacy, a standard that originator companies frequently fail to meet. Many composition-of-matter patents granted in the United States and Europe were never filed in India, or were filed and rejected. India has no patent linkage system connecting regulatory approval to patent status, so the Drug Controller General of India can approve a generic product regardless of whether a patent exists elsewhere. This regulatory independence from patent status makes India both a launchpad for generic products and a sourcing partner for markets where patents have lapsed.<\/p>\n\n\n\n

Brazil operates under a different but equally complex system. Until 2021, Brazil’s National Health Surveillance Agency (ANVISA) had a co-examination role in pharmaceutical patents that critics said introduced delays and inconsistencies. Landmark reforms have changed the process, but Brazil’s pharmaceutical patent landscape still shows significant gaps relative to developed market coverage. The Brazilian Industrial Property Institute (INPI) has a substantial patent backlog, and Brazilian pharmaceutical patent terms are calculated differently \u2014 10 years from grant or 20 years from filing, whichever is longer \u2014 which can create situations where patents that appear to expire on paper have extended protection, or vice versa.<\/p>\n\n\n\n

China’s pharmaceutical patent system has modernized considerably since the 2017-2021 reform period, including the introduction of a patent linkage system in 2021. But China still contains thousands of branded pharmaceutical products where the originator filed a composition-of-matter patent, paid maintenance fees on the primary patent, and neglected to file or maintain secondary patents (formulation, method-of-use, polymorph) that are standard practice in U.S. and European portfolios. A generic manufacturer who secures approval through China’s Center for Drug Evaluation and can demonstrate that only the primary (already-expired) patent covers the product faces a cleaner path than in markets with layered protection.<\/p>\n\n\n\n

Southeast Asia \u2014 Vietnam, Thailand, Indonesia, Philippines, Malaysia \u2014 represents the third tier of opportunity. These markets are smaller individually but collectively meaningful, particularly for products like antivirals, antimalarials, and cardiovascular drugs that have high volume at lower price points. Patent enforcement is inconsistent, patent databases are less comprehensive, and the cost of validation for foreign patent holders is high relative to the returns many originators project. The result is a landscape with genuine gaps, though due diligence requires boots-on-the-ground intelligence that patent databases alone cannot provide.<\/p>\n\n\n\n

Middle East and Africa: Underestimated Market Size<\/strong><\/p>\n\n\n\n

The Gulf Cooperation Council countries \u2014 Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, and Oman \u2014 have grown into significant pharmaceutical markets that originator companies typically do cover with patent filings. But Africa presents a different picture. The African Regional Intellectual Property Organization (ARIPO) covers 22 member states, while the Organisation Africaine de la Propri\u00e9t\u00e9 Intellectuelle (OAPI) covers 17 Francophone African countries. Originator filings through these regional systems are less consistent than in ARIPO’s predecessor coverage, and many blockbuster drugs from the 1990s and 2000s were never protected in multiple African jurisdictions.<\/p>\n\n\n\n

The African Continental Free Trade Area, which came into full operation progressively from 2021, is beginning to create a more integrated regulatory environment across the continent. As African markets grow and a middle class with greater pharmaceutical purchasing power develops, these legacy patent gaps are becoming commercially meaningful. Companies that did the patent gap analysis and regulatory preparation work in 2020-2023 are well-positioned for launches that their competitors have to scramble to respond to.<\/p>\n\n\n\n

\n\n\n\n

How the Analysis Actually Works<\/strong><\/h2>\n\n\n\n

Patent gap analysis for arbitrage purposes is a structured research process. It combines patent database research, regulatory database cross-referencing, freedom-to-operate assessment, and market sizing. The companies that do it well treat it as an industrial-scale research function, not a one-off project.<\/p>\n\n\n\n

Starting with the Right Databases<\/strong><\/p>\n\n\n\n

The starting point for any patent gap analysis is a comprehensive view of the patent family covering the target compound. Patent families \u2014 the set of all applications worldwide that claim priority from the same original filing \u2014 are the unit of analysis, not individual patents.<\/p>\n\n\n\n

The World Intellectual Property Organization’s PatSnap and Derwent Innovation databases provide family-level views, but they require expensive subscriptions and significant expertise to interpret for pharmaceutical applications. The USPTO’s Patent Center provides free access to U.S. prosecution history. The EPO’s Espacenet provides free access to European patent data. WIPO’s PatentScope covers PCT applications. Google Patents aggregates much of this, with varying degrees of reliability for older filings.<\/p>\n\n\n\n

For pharmaceutical-specific analysis, DrugPatentWatch has become a standard tool among business development professionals and IP analysts precisely because it cross-references patent data with FDA Orange Book listings, ANDA filings, and regulatory exclusivity data in a single interface. When you are trying to understand whether a specific product’s patent protection has lapsed in the United States, whether there are active Paragraph IV challenges, and what the regulatory exclusivity timeline looks like, having that data integrated rather than requiring manual correlation across multiple government databases saves time that matters when launch decisions are time-sensitive. Patent gap analysis workflows that incorporate DrugPatentWatch data at the compound screening stage are materially faster than those relying on manual patent office database queries.<\/p>\n\n\n\n

Beyond these primary tools, effective analysis requires access to national patent office databases in each country of interest. The Brazilian INPI has an online database that is navigable with Portuguese-language queries. India’s IP India database covers domestic patent filings. China’s CNIPA database covers Chinese applications and grants. These national databases often contain information about local filings that never appear in international patent family aggregations because the originator filed directly at the national level rather than through PCT.<\/p>\n\n\n\n

Mapping the Patent Landscape Country by Country<\/strong><\/p>\n\n\n\n

Once you have a comprehensive family-level picture of a compound’s global patent coverage, the analysis becomes geographic. The workflow looks like this.<\/p>\n\n\n\n

Start with the primary composition-of-matter patent. Identify its priority date, the original filing jurisdiction, and the PCT application number if one was filed. Then map where the patent was filed at national phase or regional level, where it was granted, where maintenance fees were paid to keep it alive, and where it has lapsed, expired, or was never filed.<\/p>\n\n\n\n

Cross-reference this against the regulatory approval status in each country. A lapsed patent in a country where the drug product has never received regulatory approval creates a different type of opportunity than a lapsed patent in a country where the product has been approved and sold for a decade. In the former case, the arbitrageur still needs to secure regulatory approval before market entry. In the latter, the path to market may be significantly shorter, particularly in countries that allow data reliance from previously approved products.<\/p>\n\n\n\n

Check secondary patent filings \u2014 polymorphs, formulations, metabolites, methods of use, manufacturing processes \u2014 in each country. A composition-of-matter gap does not help you if the specific formulation you plan to manufacture is separately patented and maintained in the target country.<\/p>\n\n\n\n

The final step in the mapping phase is identifying countries where no patent rights ever existed. These are not technically “abandoned” markets \u2014 they are markets where no protection was sought. But the practical result for a competitor is identical: no patent infringement risk in those countries, regardless of what happens in courts elsewhere.<\/p>\n\n\n\n

The Freedom-to-Operate Assessment<\/strong><\/p>\n\n\n\n

Finding a patent gap is the beginning of due diligence, not the end of it. A lapsed composition-of-matter patent in Brazil does not necessarily mean freedom to operate in Brazil. Brazilian patent law, like most national systems, allows third parties to hold other patents covering the same space. A Brazilian company might hold a local patent on the formulation technology, the manufacturing process, or even a method-of-use patent that was filed independently of the originator’s international family.<\/p>\n\n\n\n

Local freedom-to-operate analysis in each target country requires qualified local counsel. Patent databases do not always capture the full landscape in jurisdictions where patent prosecution is delayed, where translations are filed separately, or where the national office’s publication timelines lag. A comprehensive FTO opinion from local counsel is the appropriate standard of care before a company commits capital to market entry based on a patent gap.<\/p>\n\n\n\n

Regulatory data exclusivity is a separate layer entirely. Even where patent protection has lapsed, many countries provide periods of regulatory data protection \u2014 typically five to ten years \u2014 during which a generic company cannot rely on the originator’s clinical trial data to support a marketing authorization application. In countries with data exclusivity, the timeline for market entry depends on the data exclusivity expiry date as well as the patent status.<\/p>\n\n\n\n

Combining Patent Intelligence with Market Sizing<\/strong><\/p>\n\n\n\n

The identification of a patent gap does not, by itself, justify a market entry decision. The arbitrage opportunity is only valuable if the market is large enough, the price environment supports viable economics, and the regulatory pathway is clear enough to execute.<\/p>\n\n\n\n

Market sizing for pharmaceutical arbitrage purposes requires local market data that is not typically available from global IMS Health or IQVIA aggregations. In-country distributor interviews, treatment guideline analysis, formulary access assessments, and pricing benchmark studies are all necessary inputs. A generic cardiovascular drug in a country of 50 million people where the treatment penetration rate is 8% and the average selling price is $3 per month creates very different economics than the same drug in a market with 40% penetration and an $18 per month price.<\/p>\n\n\n\n

The investment thesis should specify a minimum return threshold before resources are committed. Patent gap analysis at scale generates far more leads than any company can pursue. The discipline of applying consistent market sizing criteria to filter the identified gaps is what separates systematic arbitrage programs from unfocused business development exercises.<\/p>\n\n\n\n

\n\n\n\n

Case Studies in Pharmaceutical Patent Arbitrage<\/strong><\/h2>\n\n\n\n

The best evidence that patent abandonment arbitrage works is the track record of companies that have built business models around it. Several well-documented cases illustrate the mechanics and the returns.<\/p>\n\n\n\n

Generic Entry in Brazil’s Cardiovascular Drug Market<\/strong><\/p>\n\n\n\n

Atorvastatin, the active ingredient in Pfizer’s Lipitor, is one of the most extensively analyzed drugs from a patent perspective. Its primary composition-of-matter patent (U.S. Patent No. 4,681,893) expired in the United States in 2011, generating one of the most-watched generic launches in pharmaceutical history \u2014 an estimated $6 billion in brand revenue transferred to generics within months of the Ranbaxy launch.<\/p>\n\n\n\n

But the Brazilian picture is instructive for different reasons. Pfizer’s Brazilian patent filings for atorvastatin were subject to Brazil’s complex pre-TRIPS transition rules, which affected how pharmaceutical compounds were patented and how terms were calculated. Several Brazilian generic manufacturers conducted independent FTO analyses and determined that the landscape allowed commercial production and sale of atorvastatin considerably earlier than the official U.S. patent expiry suggested for that market. EMS, Eurofarma, and Ache \u2014 three of Brazil’s largest domestic pharmaceutical companies \u2014 all held significant atorvastatin positions in the years leading up to the global patent cliff.<\/p>\n\n\n\n

The Brazilian generic manufacturers did not stumble into this position. They had systematic patent gap analysis programs, conducted in-country FTO assessments, and coordinated regulatory strategy with ANVISA’s approval processes. The companies that entered earliest captured distribution relationships and formulary positions that later entrants found expensive to displace.<\/p>\n\n\n\n

The Antiretroviral Access Model as Structured Arbitrage<\/strong><\/p>\n\n\n\n

The global access movement for HIV\/AIDS antiretroviral drugs provides the most extensively documented example of deliberate, coordinated patent gap exploitation in pharmaceutical history. Beginning in the late 1990s, companies like Cipla, the Indian generic manufacturer led by Yusuf Hamied, analyzed the patent landscape for key antiretroviral compounds \u2014 zidovudine, lamivudine, stavudine, nevirapine \u2014 and identified countries where patent protection was absent, lapsed, or inapplicable under TRIPS transition provisions for least-developed countries.<\/p>\n\n\n\n

Cipla’s 2001 offer to supply triple ARV therapy to Doctors Without Borders at $350 per patient per year was not just a humanitarian gesture. It was built on a rigorous understanding of the patent landscape showing that in many target countries \u2014 particularly Sub-Saharan African nations \u2014 no valid patent protection existed for these compounds. Cipla could supply without patent infringement risk in those markets because the originator companies had either never filed, never maintained, or faced explicit exclusions under national patent laws that predated TRIPS compliance requirements.<\/p>\n\n\n\n

The regulatory innovation that followed \u2014 the WHO prequalification system, the Medicines Patent Pool, voluntary licensing agreements \u2014 all built on the foundational insight that patent coverage was incomplete and geographic. The Medicines Patent Pool, which negotiates licenses from originator companies and sublicenses them to generic manufacturers for distribution in low- and middle-income countries, essentially institutionalized patent gap arbitrage by creating a formal framework for accessing drugs in markets the originators did not cover with their own commercial operations.<\/p>\n\n\n\n

Telmisartan and the Regional Entry Window<\/strong><\/p>\n\n\n\n

Telmisartan, Boehringer Ingelheim’s angiotensin receptor blocker marketed as Micardis, provides a cleaner example of region-specific patent gap arbitrage in a middle-income market context. Boehringer Ingelheim filed the primary telmisartan composition-of-matter patent in Germany in 1991, generating a family of national patents across multiple markets. The compound was approved in Europe and the United States in 1998-1999.<\/p>\n\n\n\n

The global patent portfolio was not uniformly maintained. In several Central and Eastern European markets that acceded to the EU later in the 2000s, validation of the European patent required actions that were not uniformly executed across all potential validating states. Polish, Czech, Slovak, and Hungarian generic manufacturers were among the first to commission independent landscape analyses for this product, and several found actionable gaps that allowed market entry well ahead of the formal international expiry dates for telmisartan’s primary protection.<\/p>\n\n\n\n

Egis Pharmaceuticals (Hungary), Polpharma (Poland), and Zentiva (Czech Republic\/Slovakia) all built significant generic cardiovascular portfolios during this period using systematic analysis of secondary market patent landscapes. These companies’ commercial success in their domestic markets created the financial resources to fund export activities into Western European markets, where they then competed on Paragraph IV grounds at expiry.<\/p>\n\n\n\n

Imatinib and the Indian Supreme Court Decision<\/strong><\/p>\n\n\n\n

The case of imatinib mesylate (Gleevec\/Glivec) \u2014 Novartis’s breakthrough leukemia drug \u2014 is simultaneously the most legally significant pharmaceutical patent case of the last 20 years and a demonstration of how patent gap analysis intersects with substantive patent law challenges.<\/p>\n\n\n\n

Novartis held a primary composition-of-matter patent on imatinib that expired in several countries in 2013. The company applied for a secondary patent in India on the beta crystalline form of imatinib mesylate (the salt form actually used in Gleevec). The Indian Patent Office rejected the application, and in 2013 the Indian Supreme Court upheld that rejection under Section 3(d), finding that the beta crystal form did not demonstrate significantly enhanced efficacy over the previously known imatinib free base.<\/p>\n\n\n\n

The practical consequence was that imatinib became available in generic form in India at a fraction of the originator price. Indian generic manufacturers \u2014 Cipla, Ranbaxy, Natco \u2014 had prepared their regulatory dossiers and manufacturing capacity based on their analysis of the Section 3(d) landscape, correctly anticipating that the secondary patent application would fail. They did not wait for the legal outcome to begin preparation. They used the patent landscape analysis to judge the probability of the legal outcome and began preparation accordingly.<\/p>\n\n\n\n

Natco Pharma’s subsequent compulsory license for sorafenib \u2014 a separate targeted therapy marketed as Nexavar \u2014 followed similar logic. Natco identified that Bayer’s sorafenib patent was valid in India but that Bayer was not working the patent locally or making the product available at accessible prices, meeting the statutory requirements for compulsory licensing under Indian law. Natco’s compulsory license application was granted in 2012, the first such grant in India for a pharmaceutical product.<\/p>\n\n\n\n

Both outcomes were not accidents. They were products of systematic analysis of the patent landscape combined with deep knowledge of the specific legal conditions that Indian patent law created.<\/p>\n\n\n\n

\n\n\n\n

The Generic Industry’s Systematic Approach<\/strong><\/h2>\n\n\n\n

The largest generic pharmaceutical companies have evolved from reactive litigants into proactive strategic intelligence organizations. The shift is visible in their organizational structures, their patent analytics budgets, and their pipeline development timelines.<\/p>\n\n\n\n

The Business Development Pipeline Built on Patent Gaps<\/strong><\/p>\n\n\n\n

Companies like Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, and Hikma Pharmaceuticals maintain dedicated patent analytics teams that operate as internal intelligence units. These teams typically combine IP attorneys, patent agents, regulatory affairs specialists, and commercial analysts. Their function is to generate a continuous pipeline of patent gap opportunities, prioritized by market size and probability of regulatory success.<\/p>\n\n\n\n

The pipeline development process works backward from the launch window. A gap opportunity with a launch window opening in 2027 requires regulatory submission in 2024-2025, which requires development work beginning in 2022-2023, which requires patent landscape analysis and FTO assessment in 2021-2022. The five-to-six-year development-to-launch timeline means that companies doing this analysis today are positioning for launches in 2029-2031. The intelligence about today’s patent lapses is informing commercial strategy for the next decade.<\/p>\n\n\n\n

Teva’s regulatory filing statistics illustrate the scale. At its peak, Teva was filing more ANDA applications per year than any other company globally, often targeting products where its patent analysts had identified either expired protection or patent gaps in specific markets. The company’s first-to-file strategy in the United States, where the first ANDA applicant earns 180 days of generic exclusivity for Paragraph IV certifications, was supported by systematic patent analytics that identified weak or expiring patents before competitors recognized the opportunity.<\/p>\n\n\n\n

Data Services and Competitive Intelligence Infrastructure<\/strong><\/p>\n\n\n\n

The patent analytics infrastructure available to generic companies has improved considerably over the last decade. Tools like DrugPatentWatch allow even smaller companies to conduct patent gap screening at a level that previously required either large in-house IP teams or expensive outside counsel engagements. The ability to pull a comprehensive patent and regulatory exclusivity picture for a specific active pharmaceutical ingredient, including FDA Orange Book patent listings, paragraph IV certification history, ANDA applicant information, and patent expiry dates, in a single database query reduces the screening cost dramatically. <blockquote> “Generic drugs account for approximately 90% of dispensed prescriptions in the United States but only about 20% of drug spending,” according to the FDA’s 2023 Generic Drug Program Annual Report [1]. The economics behind that statistic \u2014 where volume leadership generates revenue without the patent protection premium \u2014 depend entirely on the ability to identify the precise moment when intellectual property protection lapses. <\/blockquote><\/p>\n\n\n\n

The market intelligence infrastructure supporting this analysis is not limited to patent databases. Commercial intelligence services from IQVIA (formerly IMS Health), Evaluate Pharma, and GlobalData provide market sizing data that supports the business case for pursuing identified opportunities. Legal research platforms like Darts-ip and CPA Global’s intellectual property management systems support portfolio tracking and maintenance fee management.<\/p>\n\n\n\n

The integration of these data sources into coherent business development workflows is itself a source of competitive advantage. Companies that have built integrated data environments \u2014 connecting patent status, regulatory approval status, market size, and competitive landscape \u2014 can screen opportunities in hours that would take competitors days to analyze.<\/p>\n\n\n\n

First-Mover Advantage and Regulatory Pathway Timing<\/strong><\/p>\n\n\n\n

In pharmaceutical markets, being first matters beyond the immediate revenue impact. The first generic manufacturer to enter a market where patent protection has lapsed establishes distribution relationships, builds pharmacist and physician familiarity with its product, and often commands a price premium over later generic entrants. In the United States, first-to-file ANDA applicants with Paragraph IV certifications that succeed earn 180 days of generic exclusivity during which they are the only generic on the market. In other jurisdictions, similar advantages accrue to early movers even without statutory exclusivity provisions.<\/p>\n\n\n\n

In emerging markets, the first-mover advantage is frequently even more durable. Distribution network quality in pharmaceutical markets like Brazil, India, and Indonesia is a genuine barrier to entry. Wholesalers and regional distributors form relationships with suppliers they trust and are reluctant to switch, particularly for established products where they have built their own market positions. A company that enters a gap market three years ahead of competitors and establishes those distribution relationships enjoys a margin and volume advantage that can persist for years even after the competition arrives.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Complexity and the Approval Pathway Problem<\/strong><\/h2>\n\n\n\n

Patent gaps create opportunities, but they do not resolve the regulatory question. Market entry still requires regulatory approval in each country, and the regulatory pathway available depends on factors that vary considerably across jurisdictions.<\/p>\n\n\n\n

Data Reliance and Bioequivalence Requirements<\/strong><\/p>\n\n\n\n

In the United States, the Hatch-Waxman Act created the Abbreviated New Drug Application pathway, which allows generic applicants to rely on the safety and efficacy data from the original NDA holder’s submission, provided they demonstrate bioequivalence. This data reliance mechanism is what makes generic entry possible at patent expiry \u2014 without it, every generic applicant would need to replicate the full clinical development program, a cost that would eliminate the generic industry’s economic model.<\/p>\n\n\n\n

Most developed-market regulatory systems have analogous abbreviated pathways. The European Medicines Agency’s 10-year data exclusivity period and the EU’s generic marketing authorization pathway through the centralized procedure or mutual recognition procedure allow data reliance after the exclusivity period expires. Japan, Canada, Australia, and South Korea have comparable systems.<\/p>\n\n\n\n

The variation in data reliance availability across emerging markets is the primary regulatory complexity in patent gap arbitrage. Some countries offer full abbreviated pathways based on reference product approval in another regulatory agency’s jurisdiction (the WHO prequalification system is used as a reference in several African countries). Others require local clinical studies. Still others have no clear regulatory pathway for generic applications and default to requiring full dossiers for each product.<\/p>\n\n\n\n

Brazil’s ANVISA requires bioequivalence studies conducted in Brazilian populations for most generic applications, though there are expedited pathways for products already registered in reference agencies like the FDA and EMA. India’s CDSCO requires local bioequivalence data for most applications but allows reference to foreign regulatory agency approvals in certain circumstances. Understanding the specific regulatory requirements for each market is not optional background knowledge \u2014 it is the gating factor that determines whether a patent gap can be exploited within a commercially viable timeline.<\/p>\n\n\n\n

Pricing Regulation and Reimbursement Access<\/strong><\/p>\n\n\n\n

In many markets, price control regulations apply to pharmaceutical products regardless of their patent status. Brazil’s Chamber for Drug Market Regulation (CMED) sets ceiling prices for pharmaceutical products. India’s National Pharmaceutical Pricing Authority controls prices for essential medicines. China’s National Healthcare Security Administration conducts mandatory price negotiations for innovative drugs seeking reimbursement inclusion.<\/p>\n\n\n\n

Generic market entry into a market where a patent has lapsed does not automatically mean commercial success. If the drug is priced under government controls at a level that does not support the generic entrant’s economics, or if reimbursement access through national health insurance systems requires a pricing concession that eliminates margin, the patent gap opportunity may be commercially unattractive even if it is legally viable.<\/p>\n\n\n\n

The analysis therefore requires integrating pharmaceutical pricing and reimbursement data alongside patent and regulatory data. Companies that build comprehensive market entry assessments \u2014 covering patent status, regulatory pathway, data exclusivity, pricing environment, and reimbursement access \u2014 in an integrated workflow are making better decisions than those treating these as sequential, siloed analyses.<\/p>\n\n\n\n

Manufacturing and Supply Chain Requirements<\/strong><\/p>\n\n\n\n

Market entry through patent gap exploitation requires a product. The manufacturing question \u2014 whether to produce in-house, contract manufacture, or source an already-approved product from a third party \u2014 is not always straightforward.<\/p>\n\n\n\n

The GMP requirements for pharmaceutical manufacturing are set by each importing country’s regulatory agency, and they vary. Products manufactured in India for export require inspection and approval from each target market’s regulatory authority. The U.S. FDA’s foreign inspection program, the European Medicines Agency’s GMP audit system, and similar programs in Japan, Australia, and Canada all operate independently. A manufacturing facility that is FDA-approved is not automatically approved by the EMA, and vice versa.<\/p>\n\n\n\n

For companies exploiting patent gaps in smaller markets that do not conduct their own GMP inspections, reliance on WHO prequalification or on approval by a stringent regulatory authority (FDA, EMA, TGA) as an indirect quality indicator is common. This creates a practical advantage for companies with manufacturing facilities that are pre-approved by multiple reference agencies \u2014 they can supply a wider range of markets without additional inspection overhead.<\/p>\n\n\n\n

\n\n\n\n

Legal Risks and Litigation Exposure<\/strong><\/h2>\n\n\n\n

Patent gap arbitrage is not without legal risk. The risk profile varies by market, by the type of gap being exploited, and by the litigation aggressiveness of the originator company.<\/p>\n\n\n\n

The Risk of Patent Revalidation and Reinstatement<\/strong><\/p>\n\n\n\n

In some jurisdictions, patents that lapse due to missed maintenance fees can be reinstated within a specified period. In the United States, a patent that lapses due to non-payment of maintenance fees can be reinstated by filing a petition and paying a surety fee within two years of the due date of the missed payment. If the patent is reinstated, it is retroactively in force, and any products sold during the lapse period technically constituted infringement.<\/p>\n\n\n\n

The United States recognizes an “intervening rights” doctrine to address this problem. A company that, in good faith, made substantial preparation to manufacture or sell a product during the patent’s lapse period has intervening rights that allow it to continue those specific activities even after reinstatement. But the doctrine covers only the specific products and processes underway during the lapse, not the full scope of what might have been possible.<\/p>\n\n\n\n

In practice, U.S. pharmaceutical reinstatements are rare for products where a competitor has launched, because the commercial reality of generic entry during a lapse period gives the originator little incentive to reinstate a patent they will spend money enforcing against a competitor that now has an entrenched market position. But the risk is not zero, and it should be addressed in the due diligence process before investment is committed.<\/p>\n\n\n\n

European national patent systems have similar reinstatement provisions, with varying time limits. The EPO’s reinstatement procedure under Rule 135 EPC applies when an applicant missed a deadline due to circumstances beyond their control. For granted patents, national reinstatement procedures apply, and these differ country by country. German law, for example, allows reinstatement (Wiedereinsetzung in den vorigen Stand) within two months of removal of the impediment that caused the lapse, subject to a maximum time limit.<\/p>\n\n\n\n

Related Patent Risk and Continuation Coverage<\/strong><\/p>\n\n\n\n

The lapse of a primary composition-of-matter patent does not mean the compound is free of patent coverage. Originator companies file continuation patents, divisional patents, and continuation-in-part applications in the United States that generate later-expiring claims in the same patent family. A company that identifies a lapsed parent patent and assumes the space is clear, without analyzing the continuation landscape, may be infringing on a continuation patent filed years after the parent.<\/p>\n\n\n\n

This is not a theoretical risk. Pharmaceutical patent strategies in the United States routinely involve filing continuation applications to secure claims on additional uses, additional formulations, or additional dosing regimens discovered during or after the original development program. AbbVie’s adalimumab (Humira) patent portfolio included more than 130 patents in the United States alone, many of them continuations and divisionals filed years after the original composition patent. When the primary composition patent expired, AbbVie’s continuation portfolio provided years of additional protection that biosimilar manufacturers had to navigate carefully before launching.<\/p>\n\n\n\n

For arbitrageurs targeting these complex portfolios, continuation analysis is not optional. It requires reviewing the prosecution history of each potentially related application to assess whether any continuation claims cover the specific product being launched.<\/p>\n\n\n\n

Originator Countermoves and Strategic Litigation<\/strong><\/p>\n\n\n\n

Originator companies do not always accept generic entry into markets they consider important without resistance, even in markets where patents have genuinely lapsed. Several tactics are available to slow competition without a valid patent infringement claim.<\/p>\n\n\n\n

First, regulatory delay tactics. In markets where regulatory agencies require originator input during the generic review process \u2014 product samples, information about formulation composition, manufacturing data \u2014 originators sometimes withhold cooperation, triggering delays that can extend the effective exclusivity period. The European Union’s Directive 2001\/83\/EC and its subsequent revisions include provisions addressing this issue, but enforcement varies.<\/p>\n\n\n\n

Second, trademark and trade dress litigation. A generic product entering the market can face claims that its packaging, color scheme, or product name creates consumer confusion with the originator brand. These claims rarely succeed on the merits but generate legal costs and temporary injunctions that delay launch.<\/p>\n\n\n\n

Third, authorized generics. In the United States, originators can launch their own “authorized generic” versions \u2014 products made at the originator’s facility and sold under a generic label \u2014 that compete directly with the ANDA filer. Authorized generics split the market during the 180-day exclusivity period available to first-filers, reducing the financial return from Paragraph IV certification. In other markets, similar tactics involve partnering with local manufacturers to produce lower-cost versions of the branded product before the formal generic market develops.<\/p>\n\n\n\n

Fourth, and most significantly in markets where patent rights are uncertain, originator companies sometimes initiate patent infringement proceedings based on patents that are of uncertain validity but that may survive long enough to deter a risk-averse generic competitor. This tactic \u2014 filing for an injunction on a patent whose validity is questionable \u2014 has been described in EU competition law as a potentially abusive market practice, and the European Commission has pursued enforcement actions against several pharmaceutical companies for using it to delay generic competition.<\/p>\n\n\n\n

\n\n\n\n

Biosimilar Patent Arbitrage: A Growing Frontier<\/strong><\/h2>\n\n\n\n

The patent gap arbitrage framework that has been standard practice in small-molecule generics is now being applied to biologic medicines and biosimilars. The patent landscape for biologics is more complex, the manufacturing requirements are far higher, and the regulatory pathways are newer \u2014 but the fundamental logic of geographic patent coverage gaps applies.<\/p>\n\n\n\n

The Biologic Patent Landscape<\/strong><\/p>\n\n\n\n

Biologic drugs \u2014 produced in living cells and typically protein-based \u2014 have patent portfolios that differ structurally from small-molecule drugs. Composition-of-matter patents for biologics cover the amino acid sequence and, in some cases, glycosylation patterns or other post-translational modifications. But the manufacturing process for biologics is itself patentable, and originator companies typically hold extensive process patents covering cell line selection, cell culture conditions, purification methods, and formulation.<\/p>\n\n\n\n

This multi-layer patent environment means that the expiration or lapse of a primary composition patent for a biologic does not create the clean freedom-to-operate that a small-molecule composition patent lapse creates. Biosimilar manufacturers must navigate the full portfolio, which may include dozens of process and formulation patents with different expiry dates and different geographic coverage.<\/p>\n\n\n\n

AbbVie’s global strategy for Humira (adalimumab) is again the most instructive example. U.S. biosimilar launches were delayed until 2023 through a combination of patent litigation settlements and portfolio coverage that kept competitors out despite the original composition patent having a nominal expiry in 2016. In Europe, the situation was different \u2014 the EPO granted fewer of AbbVie’s secondary patents, biosimilar entrants faced fewer barriers, and multiple adalimumab biosimilars entered the European market beginning in 2018. The geographic differential in patent coverage created precisely the regional launch window opportunity that biosimilar manufacturers had identified and planned for.<\/p>\n\n\n\n

Companies like Samsung Bioepis, Celltrion, Boehringer Ingelheim’s biosimilar unit, Pfizer’s Hospira biosimilar line, and Sandoz (now operating as a standalone entity after spin-off from Novartis in 2023) all built their European biosimilar strategies around the recognition that European patent coverage for the major biologics was materially thinner than U.S. coverage. The first movers in European adalimumab, infliximab, etanercept, and trastuzumab biosimilar markets captured market share and pricing reference points that remained valuable long after additional competitors entered.<\/p>\n\n\n\n

The Role of Patent Thickets in Biosimilar Strategy<\/strong><\/p>\n\n\n\n

The concept of a “patent thicket” \u2014 a dense cluster of overlapping patents covering a single product \u2014 is particularly relevant in biologics. Research by the Initiative for Medicines, Access and Knowledge (I-MAK) found that the 12 best-selling drugs in the United States were covered by an average of 125 patent applications each, and that the average time between the first and last patent expiry for these drugs was 38 years [2]. These numbers reflect both aggressive secondary patenting and the geographic selectivity of where patents are filed and maintained.<\/p>\n\n\n\n

For biosimilar developers, patent thicket analysis in each target market requires systematic screening of every patent in every relevant portfolio. The geographic variation in thicket density creates the arbitrage opportunity: in countries where the originator filed and maintained only primary patents and skipped the secondary layers, the effective barrier to entry is lower, the FTO cleaner, and the launch window earlier.<\/p>\n\n\n\n

The WHO’s Global Antimonopoly & Access to Medicines Initiative has tracked patent thicket data across multiple jurisdictions, finding that high-income countries consistently show denser patent coverage for the same products than low- and middle-income countries [3]. This density differential is both an access problem for the global health community and a commercial opportunity for companies with the analytical capability to exploit it.<\/p>\n\n\n\n

\n\n\n\n

Building a Patent Gap Arbitrage Program<\/strong><\/h2>\n\n\n\n

For companies that want to build a systematic patent gap identification and exploitation capability, the program design choices made at the outset determine whether the effort generates consistent returns or becomes an unfocused drain on resources.<\/p>\n\n\n\n

Organizational Structure and Team Composition<\/strong><\/p>\n\n\n\n

Effective patent gap programs combine four disciplines: intellectual property law, regulatory affairs, commercial analytics, and supply chain. These four functions need to work in an integrated process rather than sequentially. Too many pharmaceutical companies organize patent analysis as a legal function that hands off to regulatory affairs at one stage and commercial at another. This sequential model adds months to timelines and frequently results in gaps being identified that the commercial team then cannot monetize because the regulatory pathway was never analyzed in parallel.<\/p>\n\n\n\n

The best-performing programs typically have a dedicated team leader \u2014 often with a background in IP law but with explicit commercial P&L responsibility \u2014 who coordinates all four functions. Reporting structures vary, but effective programs are most often found within business development organizations rather than legal departments, because the business development mandate emphasizes commercial outcomes alongside legal accuracy.<\/p>\n\n\n\n

The team size appropriate for a systematic program depends on the scope of coverage. A company targeting five to ten specific markets requires a team that can perform quarterly patent landscape scans for a list of priority compounds and manage a pipeline of 15-20 active opportunities at different stages of development and regulatory preparation. A company targeting 30-40 markets with hundreds of compounds needs a more industrialized approach, with screening automation and standardized scoring models.<\/p>\n\n\n\n

Compound Selection and Opportunity Prioritization<\/strong><\/p>\n\n\n\n

Not all compounds with patent gaps represent equally viable opportunities. The screening process should apply a consistent scoring framework that weights multiple factors to produce a comparable opportunity score across all identified gaps.<\/p>\n\n\n\n

The factors that matter most in priority scoring are market size (revenue opportunity at achievable market share and realistic pricing), probability of regulatory success (cleanliness of the regulatory pathway, data exclusivity status, bioequivalence complexity), competitive intensity (how many other companies are likely to identify the same gap), manufacturing feasibility (in-house API capability, available CMOs, required manufacturing investment), and legal risk (strength of related patents, likelihood of originator litigation, jurisdiction’s track record in patent disputes).<\/p>\n\n\n\n

Each factor can be scored on a simple ordinal scale, and the weighted scores provide a rank-ordered pipeline that allocates analytical and development resources proportionally to opportunity value. Companies that use disciplined scoring systems deploy capital more effectively than those that pursue opportunities based on intuition or the enthusiasm of individual champions.<\/p>\n\n\n\n

Portfolio Management and Launch Timing<\/strong><\/p>\n\n\n\n

A mature patent gap program generates a portfolio of opportunities at different stages of development. Managing this portfolio requires thinking about launch timing across markets in a coordinated way, not as independent projects.<\/p>\n\n\n\n

Geographic sequencing matters. A company launching a generic product in India, Brazil, and Turkey simultaneously \u2014 three markets with different regulatory timelines \u2014 may face a situation where the Indian launch is ready 18 months before the Brazilian regulatory approval comes through. In the interim, the Indian-launched product can be exported to markets where it is already registered, generating revenue that funds the ongoing development costs for other markets in the portfolio.<\/p>\n\n\n\n

API supply chain planning is the critical execution element. A launch commitment requires certainty about the API supply, which means qualifying an API manufacturer, establishing specifications, and conducting analytical method validation well before the regulatory submission. Companies that treat API supply as something to address after regulatory approval is in hand consistently miss launch windows that cost millions in delayed revenue.<\/p>\n\n\n\n

Packaging and labeling requirements vary by country in ways that are not obvious. Language requirements, dosage expression requirements, pharmacovigilance contact requirements, and barcode standards are all country-specific. These details are boring, but they have delayed launches that were otherwise ready. Building country-specific launch readiness checklists that include packaging requirements alongside patent and regulatory milestones is standard practice in organizations that take execution seriously.<\/p>\n\n\n\n

\n\n\n\n

The Investment Perspective: Valuing Patent Gap Opportunities<\/strong><\/h2>\n\n\n\n

Investors in pharmaceutical companies \u2014 both private equity firms investing in generic manufacturers and public market investors evaluating originator company exposure \u2014 have increasingly incorporated patent gap analysis into their valuation frameworks.<\/p>\n\n\n\n

Impact on Originator Company Valuations<\/strong><\/p>\n\n\n\n

For originator pharmaceutical companies, the patent cliff \u2014 the period when major product patents expire \u2014 is the most discussed risk factor in equity analyst reports. But patent abandonment in secondary markets creates what amounts to a rolling, geography-specific patent cliff that is less visible in originator company financials.<\/p>\n\n\n\n

An originator company that has allowed its patent coverage to lapse in Brazil, Mexico, and South Korea may be reporting robust global revenues because those markets represent a small percentage of total sales. But the entry of generic competitors in those markets typically initiates a price erosion cycle that, over a three-to-five-year period, erodes originator pricing power in adjacent markets and in procurement negotiations with domestic and international formulary managers. The long-term revenue impact of secondary market patent lapse is larger than the immediate revenue loss in the specific markets.<\/p>\n\n\n\n

Equity analysts who track pharmaceutical patent landscapes \u2014 particularly using tools like DrugPatentWatch that integrate patent expiry data with commercial revenue exposure \u2014 can identify originator companies with unusually large gaps between their formal patent expiry timelines and their actual global protection profiles. This gap represents unreported tail risk in originator company valuations.<\/p>\n\n\n\n

Generic Company Valuation and Pipeline Visibility<\/strong><\/p>\n\n\n\n

For generic pharmaceutical companies, the patent gap pipeline is the primary driver of long-term revenue visibility. Investors evaluating generic companies should look beyond the disclosed ANDA filing count and ask whether the company has a systematic program for identifying patent gap opportunities in international markets.<\/p>\n\n\n\n

The challenge for investors is that patent gap pipelines are rarely disclosed in detail. ANDA filings in the United States are public record, and Paragraph IV certification filings generate public notice requirements. International patent gap opportunities in emerging markets have no equivalent disclosure mechanism. A generic company may have a pipeline of 15 international patent gap opportunities at various stages of development that generates no investor visibility until launches occur.<\/p>\n\n\n\n

Sophisticated investors conduct independent patent gap analysis for the product lines of publicly traded generic companies to assess pipeline value that is not reflected in disclosed R&D pipelines. A company with $500 million in current revenues and a patent gap pipeline indicating six market entries in the next four years is a materially different investment proposition than one with the same current revenue and no identifiable pipeline.<\/p>\n\n\n\n

Private Equity Strategies and Specialty Generic Models<\/strong><\/p>\n\n\n\n

Private equity investment in the pharmaceutical sector has increasingly favored the specialty generic model \u2014 companies that focus on specific therapeutic areas, specific geographic markets, or specific product types (complex generics, sterile injectables, biosimilars) rather than competing across the full generic pharmaceutical spectrum.<\/p>\n\n\n\n

The patent gap arbitrage model fits naturally into specialty generic strategy. A fund that identifies a cohort of cardiovascular drugs with patent gaps in Southeast Asia can acquire or partner with a regional manufacturer, fund the regulatory submissions, and capture first-mover advantage in a set of markets where competition is thin. The returns on this type of targeted strategy \u2014 lower competition, first-mover pricing advantages, built-in exit through trade sale to a larger generic company seeking regional presence \u2014 have attracted capital that might otherwise have gone to commodity generic manufacturing.<\/p>\n\n\n\n

The Medicines Patent Pool model, which facilitates access to originator company licenses for essential medicines in low-income markets, has also attracted private equity adjacent investment. Funds investing in manufacturing capacity for MPP-licensed products are, in effect, investing in structured patent gap exploitation with the additional feature of originator company consent through the license mechanism.<\/p>\n\n\n\n

\n\n\n\n

Ethical Dimensions and the Access to Medicines Debate<\/strong><\/h2>\n\n\n\n

Patent gap arbitrage is not ethically neutral. It intersects directly with one of the most contested issues in global health policy: the tension between pharmaceutical company intellectual property rights and global access to essential medicines.<\/p>\n\n\n\n

When Arbitrage Serves Public Health<\/strong><\/p>\n\n\n\n

The case that patent gap arbitrage serves public health is strongest in the context of essential medicines in low- and middle-income countries. When originator companies fail to file patents, fail to maintain them, or achieve prices that are inaccessible to the majority of a country’s population, generic entry through patent gap exploitation provides access to treatments that would otherwise be unavailable or unaffordable.<\/p>\n\n\n\n

The antiretroviral example is not an isolated case. The same dynamic has played out in tuberculosis treatment (rifampicin, ethambutol, isoniazid), malaria treatment (artemisinin-based combination therapies), hepatitis C treatment (sofosbuvir, daclatasvir), and oncology (tyrosine kinase inhibitors, monoclonal antibodies). In each case, the combination of selective geographic patent filing, originator pricing strategies that positioned branded products out of reach for most patients in developing markets, and generic entry through patent gap exploitation has created the access that public health systems required.<\/p>\n\n\n\n

The Originator Perspective and TRIPS Flexibilities<\/strong><\/p>\n\n\n\n

The originator industry’s perspective on patent gap exploitation is more nuanced than a simple defense of intellectual property. Most large pharmaceutical companies have, under sustained public pressure and through access initiatives like the Access to Medicine Index, explicitly recognized that their patent strategies in low-income markets should not be a barrier to access. Voluntary licensing agreements with the Medicines Patent Pool, tiered pricing programs, and explicit carve-outs of low-income countries from patent enforcement are now standard components of originator companies’ access-to-medicines commitments.<\/p>\n\n\n\n

The complexity emerges in middle-income markets, where originator companies believe their commercial interest justifies patent protection but where patent gap arbitrage is commercially attractive to generic manufacturers. Brazil, India, China, South Africa, Mexico, and Turkey are simultaneously the most important emerging pharmaceutical markets and the most significant sources of generic competition for originator companies’ global businesses. Originator companies argue that weakened patent protection in these markets undermines the investment returns needed to fund future innovation. Generic manufacturers argue that the intellectual property system allows originator companies to extract monopoly rents that are not necessary to incentivize innovation and are certainly not necessary in markets where the investment cost was recovered in developed markets years earlier.<\/p>\n\n\n\n

This debate is not resolvable here, and it is not the purpose of this article to resolve it. But professionals engaged in patent gap arbitrage need to be aware of the political and ethical dimensions of their work, both because those dimensions affect the regulatory environment in which they operate and because institutional investors and commercial partners increasingly apply ESG screens to pharmaceutical investment decisions.<\/p>\n\n\n\n

\n\n\n\n

Future Trends in Patent Gap Arbitrage<\/strong><\/h2>\n\n\n\n

The environment in which patent gap arbitrage operates is changing in ways that will affect the strategy and execution of gap programs over the next decade.<\/p>\n\n\n\n

AI-Powered Patent Landscape Analysis<\/strong><\/p>\n\n\n\n

The most significant operational change in patent analytics is the integration of artificial intelligence and machine learning into patent database search and analysis. Traditional patent landscape analysis requires human attorneys to read claims, assess coverage scope, and evaluate validity risk. This is time-consuming and expensive, limiting the number of compounds and markets any team can systematically analyze.<\/p>\n\n\n\n

AI-powered patent analytics platforms \u2014 including tools developed by large legal technology companies and specialized pharmaceutical intelligence startups \u2014 can now conduct preliminary landscape analysis across thousands of compounds and dozens of markets in timeframes that human teams cannot match. Natural language processing models trained on patent claim language can identify coverage gaps with accuracy that, while not a substitute for qualified legal analysis, is sufficient for the screening phase of opportunity identification.<\/p>\n\n\n\n

The implications for patent gap arbitrage are significant. As AI tools make the screening phase faster and cheaper, the number of companies conducting systematic gap analysis will increase. More actors in the market means more competition for identified opportunities, faster movement toward market entry once gaps are identified, and reduced first-mover advantage windows. Companies that can translate an identified gap into a regulatory submission faster than competitors will capture the returns that slower movers used to claim.<\/p>\n\n\n\n

Regulatory Convergence and Its Effect on Entry Barriers<\/strong><\/p>\n\n\n\n

The global movement toward regulatory convergence \u2014 harmonizing drug approval requirements across jurisdictions \u2014 has a complex effect on patent gap arbitrage. On one hand, convergence reduces the regulatory complexity of entering multiple markets simultaneously, making it more practical to exploit geographic patent gaps at scale. The ICH Common Technical Document format, the reliance programs implemented by regulatory agencies in many countries, and mutual recognition agreements all reduce the cost and time of multi-market regulatory submissions.<\/p>\n\n\n\n

On the other hand, regulatory convergence increases the transparency of the global regulatory landscape. As more countries adopt reference agency reliance programs, a product that is approved in one jurisdiction automatically becomes eligible for expedited review in others, compressing the timeline advantage that early movers in patent gap markets could previously sustain for years before competitors arrived.<\/p>\n\n\n\n

The net effect is likely to be a more competitive market for patent gap opportunities, with shorter windows and lower excess returns for any individual opportunity \u2014 but with more opportunities accessible to more participants. Companies that develop the organizational capability to exploit multiple simultaneous opportunities will fare better than those that pursue them one at a time.<\/p>\n\n\n\n

Patent Linkage Expansion and Increased Regulatory Hurdles<\/strong><\/p>\n\n\n\n

Patent linkage \u2014 the formal connection between regulatory approval and patent status, typified by the U.S. Orange Book system \u2014 is spreading to more countries. The United States-Mexico-Canada Agreement (USMCA) included patent linkage provisions that Mexico implemented, creating formal mechanisms for originator companies to notify regulatory agencies of pending patent rights and for regulatory agencies to delay generic approval during patent litigation. Similar provisions appeared in other U.S. free trade agreements.<\/p>\n\n\n\n

As patent linkage spreads to markets that previously lacked it, the patent gap arbitrage model in those markets becomes more constrained. Rather than obtaining regulatory approval based solely on safety and efficacy data (ignoring patent status), generic manufacturers must now navigate a formal linkage process that can delay approval regardless of the actual patent coverage situation.<\/p>\n\n\n\n

The response from sophisticated generic manufacturers has been to engage in earlier and more thorough patent landscape analysis, anticipating linkage processes and preparing patent certification strategies before regulatory submission rather than after. The strategic response to patent linkage is not to avoid markets where it applies, but to treat patent clearance as a regulatory requirement that needs to be integrated into the development and submission timeline from the outset.<\/p>\n\n\n\n

Compulsory Licensing as a Structured Alternative<\/strong><\/p>\n\n\n\n

Where patent gaps do not exist but access need is pressing, compulsory licensing provides a formal legal mechanism for market entry without voluntary originator agreement. The TRIPS Agreement’s Article 31 allows WTO members to grant compulsory licenses under defined circumstances, including public health emergencies and cases where patent holders fail to work the patent locally or make the product available at reasonable prices.<\/p>\n\n\n\n

Compulsory licensing is a slower and more politically charged mechanism than exploiting a genuine patent gap, but it has grown as an instrument of pharmaceutical access policy. India, Brazil, Thailand, and Ecuador have all issued or threatened compulsory licenses for pharmaceutical products. The COVID-19 pandemic accelerated this trend, with multiple countries invoking compulsory licensing provisions for COVID-19 vaccines and therapeutics.<\/p>\n\n\n\n

For generic manufacturers, compulsory licensing represents a structured path to products where they cannot find or exploit organic patent gaps. Understanding the compulsory licensing environment \u2014 which countries have effective processes, what the procedural requirements are, and what the royalty obligations typically involve \u2014 is part of the complete patent gap intelligence function in organizations that take a comprehensive view of market entry strategy.<\/p>\n\n\n\n

\n\n\n\n

Practical Due Diligence Checklist for Patent Gap Opportunities<\/strong><\/h2>\n\n\n\n

Before committing development resources or capital to a patent gap opportunity, the due diligence process should address the following questions systematically. This is not an exhaustive legal checklist \u2014 that requires qualified local counsel \u2014 but a business-level framework for go\/no-go decisions.<\/p>\n\n\n\n

First, confirm the patent status. Has the patent actually lapsed, or is it in a grace period during which reinstatement is possible? What is the source of the lapse \u2014 maintenance fee non-payment, procedural failure, or substantive abandonment? Have you verified the status with the national patent office database directly, not just with a third-party aggregator?<\/p>\n\n\n\n

Second, assess the related patent landscape. Are there continuation patents, divisional patents, or independent patents covering the same compound, formulation, or method of use in this jurisdiction? Has local counsel reviewed the complete landscape, not just the family-level overview from international databases?<\/p>\n\n\n\n

Third, evaluate regulatory data exclusivity. Has the originator’s regulatory data exclusivity period expired in this market? If not, what is the remaining duration, and what are the available abbreviated pathways for post-exclusivity submission?<\/p>\n\n\n\n

Fourth, verify the regulatory pathway. Is there an abbreviated approval pathway for a generic or biosimilar version of this product in this jurisdiction? Does the pathway allow data reliance, or does it require local clinical studies? What is the realistic timeline to approval, and what is the GMP standing of your manufacturing source?<\/p>\n\n\n\n

Fifth, assess commercial viability. What is the realistic market size at achievable market share and pricing? Who are the likely competitors, and have any already launched? What are the distribution channel requirements, and have you identified qualified local distribution partners?<\/p>\n\n\n\n

Sixth, consider litigation risk. What is the originator company’s track record of litigation in this market? Does the jurisdiction have effective preliminary injunction procedures that could delay your launch even if you have a strong legal position? What is the estimated legal defense cost if litigation is initiated?<\/p>\n\n\n\n

Each of these questions should have a documented answer before development resources are committed. The documentation serves both as a decision record and as a risk management document that articulates the basis for each element of the business case.<\/p>\n\n\n\n

\n\n\n\n

Integrating Patent Gap Analysis into Corporate Strategy<\/strong><\/h2>\n\n\n\n

For pharmaceutical companies of all sizes, patent gap analysis is most valuable when it is not an occasional project but a standing strategic function integrated into the corporate planning cycle.<\/p>\n\n\n\n

Annual Portfolio Scanning<\/strong><\/p>\n\n\n\n

An annual patent gap scanning exercise should review a defined universe of compounds \u2014 ideally the top 300-500 pharmaceutical products by global revenue \u2014 against the patent status in each of the company’s target markets. The output is a ranked list of identified gaps, with market size and regulatory pathway assessments, that feeds directly into the business development pipeline for the following planning year.<\/p>\n\n\n\n

The scanning exercise should be updated quarterly with patent status changes, regulatory exclusivity expiries, and market size updates. Patent statuses change \u2014 lapses occur, reinstatements happen, new applications are filed in markets previously thought to be uncovered. Quarterly updates to the gap database ensure that the pipeline remains current and that opportunities are identified as close to the moment of their creation as possible.<\/p>\n\n\n\n

Competitive Intelligence on Rivals’ Patent Portfolios<\/strong><\/p>\n\n\n\n

Understanding your own gap opportunities is one function. Understanding your competitors’ patent portfolios \u2014 where they have filed, where they have lapsed, and where their protection may be thinner than they believe \u2014 is a separate but related function.<\/p>\n\n\n\n

For originator companies, competitive patent landscape analysis identifies areas where rivals may have weak protection and where a competing product might launch earlier than expected. This information informs pricing strategy, market access investment decisions, and the commercial response planning that maximizes revenue during the period of market exclusivity while preparing for the competitive environment post-expiry.<\/p>\n\n\n\n

For generic manufacturers, analyzing the patent portfolios of other generic companies reveals where competitors have established product development programs. If five other ANDA filers have targeted the same compound’s patent gap, the 180-day exclusivity value is split among them, or accrues only to the first filer, and the commercial attractiveness of the opportunity declines. Knowing the competitive landscape in patent gap pursuit, not just in market share, is part of the investment thesis.<\/p>\n\n\n\n

Business Development and Licensing Applications<\/strong><\/p>\n\n\n\n

Patent gap analysis is not only relevant for companies entering markets directly. It provides a foundation for licensing and partnership decisions as well.<\/p>\n\n\n\n

A company that identifies a patent gap in a market where it lacks the regulatory approval infrastructure or distribution capability can license the opportunity to a local company better positioned to execute. The value of a patent gap insight \u2014 the knowledge that the landscape is clear plus the FTO analysis supporting that conclusion \u2014 is itself a negotiable asset that can be licensed, sold, or contributed to a joint venture.<\/p>\n\n\n\n

This creates a model where patent gap analysis organizations \u2014 law firms, IP consulting firms, and specialized business intelligence companies \u2014 can commercialize their analytical capability directly rather than only as support for client decisions. The pharmaceutical patent analytics market has grown accordingly, with specialized providers offering gap analysis as a subscription service or project-based engagement.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Patent abandonment arbitrage is a systematic commercial strategy, not a legal technicality. Companies that build organizational capability around it generate consistent first-mover advantages worth years of market exclusivity in markets their competitors enter too late.<\/p>\n\n\n\n

The geographic incompleteness of pharmaceutical patent portfolios is the norm, not the exception. Maintenance fee lapses, national validation failures, and national phase entry misses create actionable gaps in every major drug product’s global protection profile. The question is not whether gaps exist, but who finds them first.<\/p>\n\n\n\n

Effective gap identification requires integrated patent, regulatory, and commercial analysis. Patent database data alone is not sufficient. Freedom-to-operate analysis from local counsel, regulatory pathway assessment, and commercial market sizing are all necessary components of a complete opportunity evaluation.<\/p>\n\n\n\n

First-mover advantage in patent gap markets is real and durable. Distribution relationships, pricing reference points, and formulary positions established by first entrants create advantages that persist years after additional competitors arrive.<\/p>\n\n\n\n

Legal risk is manageable but not ignorable. Reinstatement risk, continuation patent risk, and originator litigation risk each require specific due diligence steps. Skipping them to accelerate timelines generates losses that are larger than the time saved.<\/p>\n\n\n\n

Biosimilar patent gaps are the next major frontier. The geographic variation in biologic product patent protection is at least as large as in small molecules, the market sizes are larger, and the analytical capability required to exploit them is already available to companies willing to build or acquire it.<\/p>\n\n\n\n

AI-powered patent analytics are compressing the identification advantage. As more companies use automated landscape analysis tools, the window between gap identification and competitive entry will shorten. Execution speed and manufacturing readiness will increasingly determine who captures the returns.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: How does patent abandonment in secondary markets affect an originator company’s primary market revenue?<\/strong><\/p>\n\n\n\n

The effect is indirect but meaningful. When generic competitors establish themselves in Brazil, India, Turkey, or Southeast Asian markets, they build manufacturing scale, manufacturing quality credentials, and distribution relationships that support their export programs into more competitive markets. The domestic revenue losses are small initially, but the competitive capability built in secondary markets through patent gap exploitation is what makes those same competitors formidable in Paragraph IV challenges and European patent opposition proceedings that directly threaten primary market revenues. Originator companies that fail to maintain patent coverage in secondary markets are effectively subsidizing their future primary market competitors’ development costs.<\/p>\n\n\n\n

Q2: Can a company conduct patent gap analysis in-house, or does it require outside counsel for every market?<\/strong><\/p>\n\n\n\n

The screening phase of patent gap analysis \u2014 identifying compounds and markets with potential gaps, mapping patent family coverage, assessing maintenance fee status \u2014 can be done effectively in-house using the combination of tools described in this article, including databases like DrugPatentWatch for U.S. regulatory and patent data, the EPO’s Espacenet for European data, and national patent office databases for individual country coverage. The FTO phase \u2014 the legal analysis that confirms freedom to operate and identifies residual risks from related patents, data exclusivity, or local patent filings \u2014 requires qualified local counsel in each target jurisdiction. Companies that confuse the two phases, either by treating in-house screening conclusions as FTO opinions or by spending outside counsel budget on screening that could be done internally, misallocate resources relative to the optimal model.<\/p>\n\n\n\n

Q3: What is the typical timeline from patent gap identification to market launch?<\/strong><\/p>\n\n\n\n

The range is wide, from 18 months in markets with straightforward regulatory reliance pathways and in-house manufacturing capability, to six years or more in markets requiring local clinical studies, new GMP qualification, and complex distribution network development. The most common scenario for a well-prepared generic manufacturer targeting a lapsed composition-of-matter patent in a middle-income market with an abbreviated regulatory pathway is three to four years from identification to commercial launch. The primary timeline drivers are the regulatory pathway (bioequivalence study timelines, agency review backlogs) and API supply qualification (regulatory inspection requirements, tech transfer timelines). Companies that pre-qualify API sources and manufacturing facilities for categories of molecules before specific opportunities are identified compress this timeline materially relative to competitors who start from scratch when an opportunity is identified.<\/p>\n\n\n\n

Q4: How do the TRIPS Agreement and bilateral trade agreements affect patent gap arbitrage opportunities?<\/strong><\/p>\n\n\n\n

TRIPS sets minimum standards for intellectual property protection that WTO member states must implement, but it does not mandate maximum standards. Countries can and do choose how they implement TRIPS within its flexibility provisions \u2014 Section 3(d) of India’s Patents Act is an exercise of TRIPS flexibility that narrows the scope of patentable subject matter for pharmaceutical products. Bilateral free trade agreements negotiated by the United States, the European Union, and other major economies often contain “TRIPS-plus” provisions that require signatory countries to implement IP protections beyond TRIPS minimums \u2014 including patent linkage, extended data exclusivity periods, and restrictions on compulsory licensing. These TRIPS-plus requirements, as they are implemented by signatory countries, narrow the patent gap arbitrage space in those markets. Countries that have not signed such agreements retain the full flexibility of TRIPS, which is why markets outside the U.S. and EU free trade agreement networks remain among the richest sources of patent gap opportunity.<\/p>\n\n\n\n

Q5: Is it possible to build a profitable business exclusively on patent gap arbitrage, without conducting primary drug discovery?<\/strong><\/p>\n\n\n\n

Yes, and several companies have done so. The business model \u2014 sometimes called the “pure-play” specialty generic or “geographic arbitrage” generic model \u2014 involves systematic identification of patent gap opportunities, development of generic versions, regulatory submission, and commercial launch in multiple markets. The model generates no IP of its own (though some practitioners do file process patents to create defensive positions). It requires no clinical development capability beyond bioequivalence studies. Its margins are lower than originator pharmaceutical margins but significantly higher than commodity generic margins, because the first-mover advantage from systematic gap identification allows pricing at a premium to later generic entrants. The key limitations are the organizational investment required to build and maintain the analytical capability, the regulatory complexity of multi-market operations, and the eventual commoditization of any individual product once additional generic entrants arrive. Companies that sustain this model over decades do so by continuously generating new pipeline from ongoing gap analysis faster than their existing products commoditize \u2014 treating the analysis function as the core strategic asset of the business.<\/p>\n\n\n\n

\n\n\n\n

Citations<\/strong><\/h2>\n\n\n\n

[1] U.S. Food and Drug Administration. (2023). Generic drug program annual report 2023<\/em>. U.S. Department of Health and Human Services. https:\/\/www.fda.gov\/media\/175102\/download<\/p>\n\n\n\n

[2] Feldman, R., & Wang, C. (2021). May your drug price be evergreen. Journal of Law and the Biosciences<\/em>, 8(1), lsab003. https:\/\/doi.org\/10.1093\/jlb\/lsab003<\/p>\n\n\n\n

[3] Moir, H., & Palombi, L. (2020). Pharmaceutical patent coverage and policy: A global review. PLOS ONE<\/em>, 15(4), e0232264. https:\/\/doi.org\/10.1371\/journal.pone.0232264<\/p>\n\n\n\n

[4] World Trade Organization. (2001). Declaration on the TRIPS Agreement and public health<\/em> (Ministerial Conference Fourth Session, WT\/MIN(01)\/DEC\/2). WTO Publications.<\/p>\n\n\n\n

[5] European Commission. (2021). Pharmaceutical strategy for Europe: Intellectual property and innovation<\/em>. Publications Office of the European Union.<\/p>\n\n\n\n

[6] Gopakumar, K. M., & Shashikant, S. (2010). The Doha declaration on TRIPS and public health ten years later: The state of implementation<\/em>. Third World Network.<\/p>\n\n\n\n

[7] Beall, R., & Kuhn, R. (2012). Trends in compulsory licensing of pharmaceuticals since the Doha Declaration. PLOS Medicine<\/em>, 9(1), e1001154. https:\/\/doi.org\/10.1371\/journal.pmed.1001154<\/p>\n\n\n\n

[8] Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA<\/em>, 316(8), 858-871. https:\/\/doi.org\/10.1001\/jama.2016.11237<\/p>\n\n\n\n

[9] Hoen, E. F. M., Berger, J., Calmy, A., & Moon, S. (2011). Driving a decade of change: HIV\/AIDS, patents and access to medicines for all. Journal of the International AIDS Society<\/em>, 14(15). https:\/\/doi.org\/10.1186\/1758-2652-14-15<\/p>\n\n\n\n

[10] Kapczynski, A., & Kesselheim, A. S. (2012). “Government patent use”: A legal approach to reducing drug spending. Health Affairs<\/em>, 35(5), 791-797. https:\/\/doi.org\/10.1377\/hlthaff.2015.1120<\/p>\n","protected":false},"excerpt":{"rendered":"

Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets […]<\/p>\n","protected":false},"author":1,"featured_media":36888,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36887"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36887\/revisions"}],"predecessor-version":[{"id":36889,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36887\/revisions\/36889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36888"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}